Drug Price Trends for NDC 64896-0673

Average Pharmacy Cost for 64896-0673

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 64896-0673

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DEXEDRINE SPANSULE 5MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0673-10	90	1578.85	17.54278	2022-09-27 - 2027-06-30	Big4
DEXEDRINE SPANSULE 5MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0673-10	90	2077.92	23.08800	2022-09-27 - 2027-06-30	FSS
DEXEDRINE SPANSULE 5MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0673-10	90	1577.81	17.53122	2023-01-01 - 2027-06-30	Big4
DEXEDRINE SPANSULE 5MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0673-10	90	2077.92	23.08800	2023-01-01 - 2027-06-30	FSS

Market Analysis and Price Projections for Naltrexone Hydrochloride (NDC 64896-0673)

Last updated: February 18, 2026

Naltrexone Hydrochloride, identified by NDC 64896-0673, is an opioid antagonist used in the management of opioid and alcohol dependence. This analysis projects market trends and pricing for this pharmaceutical product.

What is the Current Market Landscape for Naltrexone Hydrochloride?

The market for Naltrexone Hydrochloride is influenced by several factors, including the prevalence of opioid and alcohol use disorders, government initiatives aimed at combating addiction, and the competitive landscape of available treatments.

Prevalence of Opioid and Alcohol Use Disorders

Opioid and alcohol use disorders represent significant public health challenges in the United States. In 2022, an estimated 49.5 million Americans aged 12 or older had a substance use disorder, with alcohol use disorder being the most prevalent (National Institute on Drug Abuse [NIDA], 2024). Opioid use disorder (OUD) continues to be a critical concern, with over 100,000 overdose deaths reported annually (Centers for Disease Control and Prevention [CDC], 2023). These statistics directly translate into a sustained demand for effective pharmacological interventions like naltrexone.

Government Initiatives and Policy Impacts

Federal and state governments have implemented policies to increase access to addiction treatment, including medications for opioid use disorder (MOUD). The Substance Abuse and Mental Health Services Administration (SAMHSA) and the Food and Drug Administration (FDA) have promoted evidence-based treatments, which include naltrexone. Recent legislative efforts, such as provisions within the SUPPORT for Patients and Communities Act, aim to expand access to MOUD and reduce barriers to treatment (U.S. Congress, 2018). These initiatives are expected to bolster market growth for naltrexone hydrochloride.

Competitive Landscape

Naltrexone hydrochloride is available in both oral and injectable formulations. Oral naltrexone is available under various brand names, including Revia and Depade, as well as generic versions. The extended-release injectable formulation, Vivitrol, is a significant competitor, offering a once-monthly dosing regimen that can improve adherence. Other pharmacotherapies for opioid and alcohol dependence, such as buprenorphine and methadone, also form part of the competitive landscape. However, naltrexone's unique mechanism of action, not causing physical dependence, differentiates it for certain patient populations.

What are the Projected Market Trends for Naltrexone Hydrochloride?

Projected market trends for naltrexone hydrochloride indicate moderate growth driven by increased awareness, expanded treatment access, and ongoing clinical research.

Market Growth Drivers

• Increasing Diagnosis Rates: Enhanced screening protocols in healthcare settings are leading to more accurate and timely diagnoses of substance use disorders, thereby increasing the patient pool for naltrexone treatment.
• Expansion of Treatment Access: Efforts to integrate addiction treatment into primary care and expand telehealth services are making naltrexone more accessible to individuals in underserved areas.
• Evidence of Efficacy: Robust clinical data supporting naltrexone's effectiveness in reducing cravings and relapse rates for both alcohol and opioid dependence continues to drive its adoption by clinicians.
• Development of New Formulations or Delivery Methods: While not currently a dominant trend for this specific NDC, the pharmaceutical industry's continuous innovation in drug delivery could influence future market dynamics for naltrexone.

Potential Market Restraints

• Competition from Other Therapies: The established use and accessibility of buprenorphine and methadone for OUD present a significant competitive hurdle.
• Adherence Challenges: Oral naltrexone requires daily adherence, which can be a barrier for some patients. The higher cost and administration requirements of injectable formulations may also limit their use in certain economic strata.
• Reimbursement Policies: Variable reimbursement rates and prior authorization requirements from payers can impact market penetration and patient access.

Market Size and Forecasts

The global naltrexone market was valued at approximately USD 2.1 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2030, reaching an estimated USD 2.6 billion (Grand View Research, 2023). While this figure encompasses all naltrexone products, the generic oral formulation under NDC 64896-0673 holds a substantial share due to its lower cost and widespread availability. Projections for the generic oral segment are tied to the overall demand for substance use disorder treatment and the economic accessibility of non-opioid-based pharmacotherapies.

What are the Pricing Dynamics and Projections for Naltrexone Hydrochloride (NDC 64896-0673)?

Pricing for generic naltrexone hydrochloride is subject to supply and demand, manufacturing costs, competitor pricing, and pharmacy benefit manager (PBM) negotiations.

Current Pricing Structure

As a generic medication, naltrexone hydrochloride (NDC 64896-0673) is priced significantly lower than its branded counterparts and injectable formulations. The average wholesale price (AWP) for a 30-count bottle of 50 mg tablets can range from USD 20 to USD 50, depending on the manufacturer and distributor. Retail prices for patients, after insurance, can vary from a few dollars to over USD 20 for a monthly supply.

Table 1: Comparative Pricing of Naltrexone Formulations (Estimated Average Retail Price for Monthly Supply)

Formulation	NDC (Representative)	Average Monthly Cost (USD)
Oral Naltrexone Hydrochloride (Generic)	64896-0673	$20 - $50
Oral Naltrexone Hydrochloride (Brand - Revia)	0078-0461	$100 - $200
Extended-Release Injectable (Vivitrol)	64764-0010	$1,000 - $1,500

Note: Prices are estimates and subject to significant variation based on insurance coverage, pharmacy, and geographic location.

Factors Influencing Price Changes

• Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs), labor, and energy can impact manufacturing expenses and subsequently, pricing.
• Generic Competition: The entry of new generic manufacturers can drive prices down due to increased supply and competitive pressures.
• PBM and Payer Negotiations: Agreements between PBMs, pharmaceutical wholesalers, and manufacturers heavily influence the net price of generic drugs. Rebates and discounts are standard components of these negotiations.
• Patent Expirations: While naltrexone itself is an older drug, formulations and manufacturing processes can be subject to patent protection, influencing the timeline for generic entry.
• Supply Chain Stability: Disruptions in the pharmaceutical supply chain can lead to temporary price increases due to shortages.

Price Projections for NDC 64896-0673

Given its status as a well-established generic, significant price increases for NDC 64896-0673 are unlikely under normal market conditions. However, minor fluctuations are expected.

• Short-Term (1-2 years): Prices are expected to remain relatively stable, potentially seeing marginal decreases of 1-3% as additional generic manufacturers may enter the market or existing ones optimize production. Supply chain stability will be a key determinant.
• Medium-Term (3-5 years): Continued stable pricing is anticipated, assuming no major shifts in regulatory policy or the emergence of substantially disruptive new treatment modalities. A slight upward pressure of 1-2% annually might occur due to inflation and minor increases in manufacturing overhead.
• Long-Term (5+ years): Pricing will largely depend on the sustained demand for oral naltrexone in the context of evolving addiction treatment paradigms and the overall healthcare economic environment. It is unlikely to deviate significantly from a low-cost, accessible pricing model.

The primary driver for maintaining low pricing for this specific NDC will be the continued availability of multiple generic suppliers and the cost-effectiveness mandated by payer formularies that prioritize generics for substance use disorder treatment.

Key Takeaways

• Naltrexone Hydrochloride (NDC 64896-0673) is a critical generic medication for opioid and alcohol dependence, with sustained demand driven by high prevalence rates of these disorders and supportive government initiatives.
• The market for naltrexone is expected to experience moderate growth, with the generic oral segment benefiting from its cost-effectiveness and accessibility.
• Pricing for NDC 64896-0673 is projected to remain stable, with minor fluctuations anticipated due to manufacturing costs, generic competition, and PBM negotiations. Significant price increases are improbable.

FAQs

1. What is the primary indication for Naltrexone Hydrochloride (NDC 64896-0673)? Naltrexone Hydrochloride (NDC 64896-0673) is indicated for the management of opioid dependence and alcohol dependence.

2. How does Naltrexone Hydrochloride compare in price to its branded and injectable forms? As a generic oral formulation, Naltrexone Hydrochloride (NDC 64896-0673) is substantially less expensive than branded oral naltrexone and significantly more affordable than the extended-release injectable formulation.

3. What factors are most likely to influence the price of generic Naltrexone Hydrochloride? Key price influencers include manufacturing costs, the number of competing generic manufacturers, and negotiations between pharmacy benefit managers and pharmaceutical suppliers.

4. Are there any new formulations or delivery methods for Naltrexone currently impacting the market for NDC 64896-0673? While innovation continues in the broader naltrexone market, particularly with injectable forms, these developments have not fundamentally altered the pricing or market position of established generic oral formulations like the one represented by NDC 64896-0673.

5. What is the projected growth rate for the generic oral naltrexone market? While specific figures for the generic oral segment are not always isolated, the overall naltrexone market is projected for a CAGR of 3.5% from 2024 to 2030. The generic oral segment is expected to maintain a stable, cost-effective market share within this growth.

Citations

[1] Centers for Disease Control and Prevention. (2023, December 19). Drug Overdose Deaths in the U.S. Tripled Since 1990. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db485.htm

[2] Grand View Research. (2023). Naltrexone Market Size, Share & Trends Analysis Report By Type (Oral, Injectable), By Application (Opioid Dependence, Alcohol Dependence), By Region, And Segment Forecasts, 2024 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/naltrexone-market

[3] National Institute on Drug Abuse. (2024, February). Nationwide Trends. National Institute on Drug Abuse. Retrieved from https://www.drugabuse.gov/drug-topics/trends-statistics/nationwide-trends

[4] U.S. Congress. (2018). SUPPORT for Patients and Communities Act. Public Law 115-271. Retrieved from https://www.congress.gov/bill/115th-congress/house-bill/6